The prognostic significance of HLA-A2 expression on somatic cells in patients with left-sided colon and rectal cancers
Streszczenie
Introduction. Current knowledge about colorectal cancer (CRC) identifies tumor immunogenicity as one of the more important issues. In cancers, a prerequisite for immune system activation is the presentation of tumor associated antigen (TAA) epitopes to immunocompetent cells. HLA-A2 is one of the antigens in the context of which TAAs are present, but data on the possible impact of HLA-A2 antigen expression on the survival of patients with colorectal cancer are scarce and sometimes contradictory. The aim of this study was to analyse the relationship between HLA-A2 expression in patients with left-sided colorectal cancer in various stages of disease and their long-term survival, and to answer the question of whether a lack of HLA-A2 expression is actually a negative prognostic factor.
Material and methods. A prospective analysis of 58 patients with left-sided colorectal cancer was carried out. Expression of HLA-A2 was determined by patient blood lymphocyte staining, and analysed using flow cytometry.
Results. In the study group, patients with HLA-A2 expression lived statistically longer than HLA-A2 negative patients (p = 0.027). There was no significant difference in overall survival between the HLA-A2+ and HLA-A2- groups with stage II and III left-sided CRC. However, the Cox proportional hazard model showed that a lack of HLA-A2 expression was a negative prognostic factor in the group of radically operated patients without distant metastases.
Conclusions. HLA-A2 status may affect the clinical course of patients with left-sided colon and rectal cancer, although left-sided tumors are less immunogenic than right-sided ones. HLA-A2-positive patients with left-sided colorectal cancer lived statistically longer than those who were HLA-A2-negative (p = 0.027). Lack of HLA-A2 expression was a negative prognostic factor in the group of radically operated patients.
Słowa kluczowe: HLAHLA-A2left-sided colon canceroverall survivalprognostic biomarker
Referencje
- Pandolfi F, Boyle LA, Trentin L, et al. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res. 1991; 51(12): 3164–3170.
- Kiewe P, Mansmann V, Scheibenbogen C, et al. HLA-A2 expression, stage, and survival in colorectal cancer. Int J Colorectal Dis. 2008; 23(8): 767–772.
- Hee Lee Ji, Park MS, Hwang JE, et al. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K. Cell Mol Immunol. 2013; 10(3): 275–282.
- Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005; 33(2): 113–133.
- Madjd Z, Spendlove I, Pinder SE, et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005; 117(2): 248–255.
- Vitale M, Pelusi G, Taroni B, et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005; 11(1): 67–72.
- Gamzatova Z, Villabona L, Dahlgren L, et al. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol. 2006; 103(1): 145–150.
- De Petris L, Bergfeldt K, Hising C, et al. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol. 2004; 21(1): 49–52.
- Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006; 66(18): 9281–9289.
- Mezquita L, Charrier M, Faivre L, et al. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017; 112: 10–15.
- Dierssen JW, de Miranda NF, Mulder A, et al. High-resolution analysis of HLA class I alterations in colorectal cancer. BMC Cancer. 2006; 6: 233.
- Kloor M, Becker C, Benner A, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 2005; 65(14): 6418–6424.
- Söreide K, Janssen EAM, Söiland H, et al. Microsatellite instability in colorectal cancer. Br J Surg. 2006; 93(4): 395–406.
- Kim K, Castro EJ, Shim H, et al. Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer. Ann Coloproctol. 2018; 34(6): 280–285.
- Speetjens FM, de Bruin EC, Morreau H, et al. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother. 2008; 57(5): 601–609.
- Passardi A, Canale M, Valgiusti M, et al. Immune Checkpoints as a Target for Colorectal Cancer Treatment. Int J Mol Sci. 2017; 18(6).
- Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017; 27(1): 11–37.
- Lim DRo, Kuk JK, Kim T, et al. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? Medicine (Baltimore). 2017; 96(42): e8241.
- Benedix F, Kube R, Meyer F, et al. Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010; 53(1): 57–64.
- Derwinger K, Gustavsson B. Variations in demography and prognosis by colon cancer location. Anticancer Res. 2011; 31(6): 2347–2350.
- Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015; 21(21): 6470–6478.
- de Vries NL, Swets M, Vahrmeijer AL, et al. The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. Int J Mol Sci. 2016; 17(7).
- Löffler MW, Kowalewski DJ, Backert L, et al. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Res. 2018; 78(16): 4627–4641.
- Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350–1356.
- Sandel MH, Speetjens FM, Menon AG, et al. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol. 2005; 42(4): 541–546.
- Swets M, König MH, Zaalberg A, et al. HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases. Hum Immunol. 2016; 77(9): 773–779.
- Zeestraten ECM, Reimers MS, Saadatmand S, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer. 2014; 110(2): 459–468.
- Reimers MS, Engels CC, Putter H, et al. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer. 2014; 14: 486.
- Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer. 2010; 127(5): 1001–1010.
- Ijsselsteijn ME, Petitprez F, Lacroix L, et al. Revisiting immune escape in colorectal cancer in the era of immunotherapy. Br J Cancer. 2019; 120(8): 815–818.
